360biolabs is a contract service organisation providing specialist expertise and laboratory services for the development of new therapeutics, vaccines and diagnostics in a quality-assured environment. Diverse range of assays and biomarker endpoints for clinical trials and preclinical studies in many therapeutic areas Expertise in virology, immunology and analytical chemistry. World-class facilities with BSL-2, BSL-3 & quarantine laboratories > Quality management systems to ensure that “every sample counts”
The Australian Institute of Tropical Health and Medicine (AITHM) is a flagship research institute of James Cook University based in the tropics of northern Australia. Australia’s only dedicated tropical health and medicine research institute, AITHM is focussed on solving problems of importance to the tropics, leading to improvements in health systems and healthcare delivery, improved biosecurity, and enhanced health outcomes for Australians and our neighbouring tropical nations.
The leading Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy.
The Australian Institute for Bioengineering and Nanotechnology is an integrated multidisciplinary research institute bringing together world-class researchers and cutting-edge technology with a focus on translational research.
Avatar Brokers is a foundation partner of LSQ and a company specialising in providing insurance and risk management solutions for innovative businesses. Avatar’s notable expertise in the life sciences & technology sector aims to deliver real financial and business benefits. Avatar understands the unique requirements of the sector and takes the time to understand the specific issues & challenges facing your business.
Bellberry Limited is a national, private not-for-profit organisation providing streamlined scientific and ethical review of human research projects across Australia.
Beyond is an integrated product development team dedicated to early-stage product development, focusing primarily on advancing innovative products from small to medium biotechnology and pharmaceutical companies worldwide. As an Australian privately owned company, we provide flexible and nimble solutions to match the needs of our clients, whether it is a stand-alone activity or a full suite of services.
BiVACOR® is a privately held company founded in 2008.The BiVACOR is a total artificial heart designed to take over the complete function of a patient’s failing heart. The BiVACOR TAH is designed to be a long-term device that can replace the total function of the patient’s native heart.
Bionics Queensland connects great ideas with great minds – we bring scientists, researchers, healthcare consumers, clinicians and investors together to take bionic innovations to the next level.
Brandon Capital is Australasia's leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK.
Brisbane Economic Development Agency (BEDA) drives the sustainable economic growth of the city. As Brisbane’s champion, BEDA works closely with government and private sector organisations to enhance and promote the city’s reputation globally and drive demand for Brisbane.
CAD-IT Australia supports the life science community and is driven by a clear goal: to redefine possibilities. Our expertise lies in tailor-made digital solutions, carefully crafted to tackle the specific challenges of the sector.
The Centre for Advanced Imaging (CAI) within AIBN, is at the forefront of imaging science and is the only centre of its kind in Australia. Bringing together a critical mass of researchers and state-of-the-art preclinical and clinical research infrastructure and instruments, CAI enables world-class research through collaborations with industry and academia while fostering a rich, collaborative environment for our own experts to innovate across spectroscopic and imaging technologies. The CAI’s work is fundamental to a broad range of research fields, from major diseases affecting various organ systems, such as neurodegenerative disorders, cancer, and cardiovascular disease, through to imaging economically significant agricultural animals and plant material, minerals and construction materials. Through techniques such as Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Nuclear Magnetic Resonance (NMR) and Electron Paramagnetic Resonance (EPR) spectroscopy, as well as the state-of-the-art isotope production and radiochemistry capability within the centre, our researchers gain unique insights into the structure and function of biomolecules through to whole organisms. CAI’s impact on translational research is maximised through collaboration with clinical research sites and other local, national, and international research institutes. This gives CAI a comprehensive ‘end-to-end’ biomedical imaging capability which allows integrated progression from the laboratory bench, all the way through to a clinical setting.
Cool Beans is an innovative, cooling underwear designed to boost sperm health and improve the likelihood of conception for couples. As a medical device entered into the Therapeutic Goods Administration Registrar (ARTG 379655), our underwear finally involves men in the conception journey, empowering them to play an active role in building and expanding their family.
Corrs Chambers Westgarth provide legal services across the full spectrum of matters, including major transactions, projects and significant disputes, offering strategic advice on our clients’ most challenging issues.
Cytiva are a global provider of technologies and services that advances and accelerates the development, manufacture, and delivery of therapeutics. We’re bringing together a wealth of technical expertise and talent, broad and deep portfolio, and exceptional service to help researchers and biopharma advance therapeutics at every stage: from discovery to delivery.
Danbar Consulting works with Universities, Research Institutes, Government and the Private Sector to plan and deliver projects that create significant social, economic and opportunity value with a focus on Life Sciences, Health and Education sectors.
Dave Collison Cave provide patent, trademark, design and copyright, commercialisation, privacy and data protection and services in Australia, New Zealand, Singapore and the ASEAN region.
De Motu Cordis is a clinical based start up based in Brisbane that is developing a product platform for the emergency treatment of life-threatening conditions. DMC have developed a needle-free drug device combination for the immediate treatment of anaphalaxis.
FB Rice is a top tier leading Australian Intellectual Property firm with offices across the country and an established presence across New Zealand and South-East Asia. They extend advice beyond a pure IP focus to a more strategic, commercial level.
The Gold Coast Health and Knowledge Precinct is a global business destination recognised for transforming lives through healthcare innovation, new knowledge and next-generation technologies.
Griffith University is ranked amongst the top 3% of universities globally, and has over 50,000 students spread across 5 campuses. Griffith’s health and bioscience research institutes collaborate with industry and public health sectors to deliver global benefits through outcomes such as novel drug leads, vaccines for combating infectious diseases, and healthy living programs.
Griffith University's Clinical Trial Unit, located within the Gold Coast Health and Knowledge Precinct and adjacent to the Gold Coast University Hospital, provides state-of-the-art facilities and professional coordination services to phase I-IV clinical trials. Supporting university staff and collaborators to conduct a wide range of trials, but also offering professional clinical trial site services to commercial clients such as global pharma, contract research organisations and the biotech and nutraceutical industry.
Infensa has a unique portfolio of peptide drugs that protect neurons and heart muscle cells from ischemic injury. Most treatments being developed for MI and stroke attempt to minimise or restore damaged tissue after the event, rather than minimising the initial tissue injury.
Intellect Labs helps ambitious businesses with R&D Tax Incentive, Patent Box, Grant Strategy and IP centric projects across the medtech, biotech, food and beverage, recycling and manufacturing industries. We collaborate with an expandable network of IP experts to assist our clients to leverage the ideas and products they develop.
James Cook University (JCU) is one of the world’s leading institutions focusing on the tropics. With main campuses in the tropical cities of Townsville, Cairns and Singapore, JCU’s teaching and research are shaped by the university’s presence in Asia and its proximity to the wet tropics, dry savannahs and iconic great Barrier Reef. JCU’s focus is on the health, environment and populations of tropical regions. JCU has the Australian Institute of Tropical Health & Medicine and the Queensland Tropical Health Alliance.
James & Wells experience ranges from managing large IP portfolios for international corporations, right through to protecting the ideas of start-ups, and everything in between.
KE Select is an Australian based, leading Scientific & Medical Recruitment Partner for organisations within the Life Science, Medical, Clinical, Hospital and Healthcare space. Director Kerry McMahon (BSc Biomedical Science) has over 15 years’ experience carrying out Executive Search, Permanent and Contract based recruitment projects in ANZ and more recently into Asia-Pacific. Kerry and her team, they are passionate about tailoring to every client’s needs. The focus for KE Select is to build and maintain personal long-term relationships.
Knight Frank work in partnership with our commercial and residential clients to deliver exceptional results and unlock opportunities, together. They are the world’s largest privately-owned property consultancy, we have the distinct advantage of taking a longer term approach and investing in our client relationships versus being driven by the bottom line.
MTPConnect is a not-for-profit organization in Australia that aims to accelerate the growth of the medical technology, biotechnology, and pharmaceutical (MTP) sector. It was established in December 2015 by the Australian Government as an independent organization. MTPConnect focuses on strengthening connections between research and industry to maximize opportunities for scientific and technological breakthroughs, as well as their translation and commercialization. Their key areas of focus include increasing collaboration and commercialization, improving management and workforce skills, enhancing access to global supply chains and international markets, and optimizing the regulatory environment.MTPConnect raises awareness, facilitates collaboration, aggregates knowledge, and jointly funds projects that address sector growth priorities and identified constraints and gaps. They have established key hubs in Adelaide, Perth, and Brisbane, along with their head office in Brighton, Victoria. The MTPConnect Board, led by Hon Jaala Pulford, consists of respected industry leaders.MTPConnect also runs various programs funded by the Medical Research Future Fund (MRFF) and other initiatives, supporting research and development in the MTP sector.
Mater Research is a recognised leader in medical research. Mater Research works across Mater Health’s hospitals and health services, the University of Queensland, and the world- class Translational Research Institute.
McCullough Robertson is a leading Australian law firm, operating across multiple offices. With a history spanning over 95 years, they have gained the trust of major corporations, financial institutions, governments, and high net worth individuals. Their expertise extends to various industries, including mining, energy, food, real estate, technology, healthcare, and government. McCullough Robertson prioritizes building long-term relationships with their extensive client base, offering reliable advice for their most critical challenges.
Merck offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities. Our vision is a world where our innovative products, services, and digital offerings help create solutions for people globally and a sustainable future for generations to come.
Microba is a microbial genomics company providing the public with access to cutting-edge technology to analyse their personal gut microbiome. Using one of the most advanced sequencing technologies, Microba empowers consumers to gain a deeper understanding of their personal microbiome.Microba's therapeutic discovery is generating multiple potent therapeutic candidates to address unmet clinical needs for multiple chronic diseases, leveraging the biology of the healthy human gut microbiome.
MinterEllison provides legal and consulting services to a diverse client base across industries through offices in Australia and a global network of member firms and associated companies. In Australia, MinterEllison is one of the country's largest law firms.
information to follow
Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, New England Biolabs is now a recognized world leader in the discovery and production of enzymes for molecular biology applications.
Northwest Healthcare Properties Australia is a leading company focused on owning, managing, and developing top-tier hospital, health, and life sciences properties in Australia and New Zealand. With approximately A$6.8 billion in assets under management, they are the largest healthcare real estate owner and developer in the region. Northwest boasts a portfolio of 73 properties with around 270 tenants. They also have a robust development pipeline of approximately A$3.1 billion, with 15 committed projects, 11 of which are currently under construction.
Novartis is dedicated to improving the lives of more than 2.8 million patients across Australia and New Zealand through innovative medicines. By partnering with the healthcare system, Novartis is committed to enhancing patient access to life-saving treatments. Through cutting-edge science and technology, the company is reimagining medicine to tackle complex healthcare challenges, supported by a robust research pipeline of over 200 projects in development. Additionally, Novartis is transforming the way clinical trials are conducted, expanding access to its industry-leading clinical trials footprint in Australia to benefit more patients.
NuPlant has developed advanced robotic systems for plant tissue-culture. Our SmartClone Sirius and Gemini systems support dissections every three seconds; they unprecedently allow dynamic media change. Our Janus transplanter transfers plantlets to soil and re-assembles consumables for washing in our Neptune system for sustainable re-use. These systems flexibly provide tougher plantlets in shorter time at lower cost.
Nucleus Network's Brisbane facility, formerly known as Q-Pharm, is a dedicated clinical trial unit situated at the Royal Brisbane and Women's Hospital. As Australia's second-largest Phase 1 unit, it conducts clinical trials for companies and researchers involved in developing new, safer, and more effective medications. With over 15 years of reliable experience, Q-Pharm has successfully completed over 400 Early Phase studies and recruited over 15,000 participants. Specializing in early-phase (phases 1 and 2) clinical trials, Q-Pharm operates in a cutting-edge facility located in the Herston precinct at the Royal Brisbane and Women's Hospital in Brisbane, Australia.
OneVentures are one of Australia’s leading venture capital firms, with over $650 million in funds under management and are now looking for new opportunities in the healthcare and technology sectors. We work with companies to take them to that all important next stage, by actively shaping their future. We apply our years of experience, expertise, operational and executional excellence to accelerate their growth and launch them into global markets.
PSC Biotech is a provider of life sciences essential services, ensuring the development, manufacturing, and distribution of medical and biotech products meet regulatory standards. The Australian team specializes in GMP Engineering, offering expertise in commissioning, qualification, and validation (CQV). They assist with validation project planning, documentation generation, execution, and summary reports. Additionally, PSC Biotech offers computer system validation (CSV) and technical writing support for operational readiness. Their focus is on maintaining compliance and delivering high-quality services in the life sciences industry.
Patheon Biologics, a division of Thermo Fisher Scientific, offers comprehensive pharmaceutical services to support the entire biotechnology and pharmaceutical life cycle. Thermo Fisher's pharma services solutions aid customers in accelerating innovation and enhancing productivity in drug development and commercialization. As a strategic contract development and manufacturing organization (CDMO) and clinical services partner, they serve the pharmaceutical, biotech, and life sciences industries. At their mammalian-based cGMP facility in Brisbane, Australia, Patheon supports clients in large-scale GMP manufacturing of biopharmaceuticals.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company. We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.
QIMR Berghofer is one of Australia’s largest medical research institutes, renowned for its world-leading research in cancer, infection and inflammation, brain and mental health, and population health. QIMR Berghofer is home to almost 1,000 scientists, students and support staff in more than 60 state-of-the-art laboratories.
Queensland University of Technology (QUT) is a renowned Australian university that emphasizes a global perspective. With nearly 50,000 students, QUT offers real-world infrastructure, education, and graduate skills to empower the next generation of change-makers. Collaborating with various universities, institutions, and hospitals, QUT is dedicated to research excellence. Their research team is highly regarded for providing government, businesses, and organizations with top-notch research resources. QUT houses cutting-edge facilities and research groups focused on innovative research across various health disciplines. QUT is home to the Centre for Genomics and Personalised Health, contributing to advancements in personalized medicine.
Established in 2003, the Queensland Brain Institute is a leading research institute focused on two of the greatest challenges of modern science: understanding brain function, and preventing and treating disorders of brain function.
QIC is a trusted investment manager and adviser providing risk adjusted returns for the clients we serve. As one of Australia’s leading institutional investment managers, we deliver alternative real asset solutions across infrastructure, real estate, private debt, private capital and natural capital in addition to a liquid market offering for our 125 Australian and global clients. We also act as the Queensland Government’s independent investment advisor, managing a fully-funded Defined Benefit scheme and the Queensland Future Fund both of which delivers on the State’s long-term investment objectives. We have US$65bn in assets under management (as at 31 March 2023) and are headquartered in Brisbane, Australia, with offices in Sydney, Melbourne, New York, San Francisco and London.
We are a global drug development accelerator with over 1,300 staff operating from state-of-the-art development, manufacturing and clinical testing facilities in the U.S. and U.K. We have over 30 years of experience and have worked on over 3,000 molecules across all stages of development.
Radium Capital is Australia’s market leader in advances of the R&D Tax Incentive refund. Since launching in 2017, we’ve helped hundreds of innovators build their businesses the strategic way.
Research Collective provides Development, implementation and management of research grant operations; Grants peer review and Change Management services in the health and medical research sector.
Resolian Bioanalytics is a leading global research laboratory providing services for the pharmaceutical, biotechnology, and medical device industries.
Sanofi Australia is part of a global healthcare organisation that employs over 100,000 people across 170 countries. Our purpose is to bring hope, relief and cures to patients with the medicines and vaccines that we make. Established in Australia in 1980, our heritage spans 100 years, pioneering medicine across broad therapeutic areas including diabetes, cardiovascular disease, influenza, oncology, immunology, rare diseases and rare blood disorders. Today in Australia we are a leading supplier of diabetes medicines and vaccines. We strive to provide quality vaccination coverage from infectious diseases to all Australians. 95% of young Australian’s will have had a Sanofi vaccine by age five, and one in four Australians has had one of our flu vaccines. Due to our global manufacturing network and dedicated local team of over 700 people, we reliably supply quality innovative vaccines, medicines and healthcare solutions, throughout the country, enabling those in rural and remote locations to access our treatments. Our breakthrough science, technology and unique collaborations allow us to accelerate access to scientific innovation and benefit the lives of patients who depend on us. From the many with rare conditions, the millions with chronic disease to those seeking protection from infectious disease. In collaboration with clinicians, our clinical trials are an important phase of our research, and annually supports access for over 500 Australians to many scientific innovations including those for atopic dermatitis, multiple sclerosis and haemophilia. Inclusion and diversity are at the heart of our culture, allowing our people to feel heard, valued and respected. We embrace news ways of thinking, which is integral to innovation, and allows us to better understand, connect and meet the health needs of people in Australia.
Servatus BioPharmaceuticals Limited are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections.
We are a Australian contract development and manufacturing organisation (CDMO) specialising in the production of nucleic acid products (mRNA) that support life-enabling work. We support our customers by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field. Developing and deploying our state-of-the-art bioprocessing and chemical process technologies, using proprietary manufacturing approaches, employing a highly-skilled Australian workforce.
%20(1).png)
.jpg){kind=logo}
.jpg)
.png)
.png)
.png)
